Theriva Biologics fails to convene special meeting due to lack of quorum; will call new meeting

Theriva Biologics, Inc.

Special Meeting on April 9, 2026 lacked quorum; meeting could not convene.
Company will call new meeting to seek approval for issuance of up to 16,184,560 shares upon exercise of New Warrants.
Under Inducement Agreement dated Oct 16, 2025, company must continue calling meetings every 60 days until approval or warrants expire.
Stockholders will receive new proxy materials with date/time of adjourned meeting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.